Junshi Biosciences Announces 2022 Interim Financial Results and Provides Corporate Updates
-- Clinical trials of core drug candidates are progressing steadily with the debut of the company's FIH asset -- Toripalimab's sales performance is consistently improving; the US BLA is under review SHANGHAI
United States Junshi Bioscience Junshi Biosciences Zhi Li Acta Pharmacologica Sinica American Society Of Clinical Oncology
Source: finanznachrichten.de